Form D · Biotechnology
Vanquish Oncology, Inc.
Champaign, IL · CIK 0001572746
Offering snapshot reported Jul 1, 2020 · SEC filing
- Reported sold
- $500K Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jun 30, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2020 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jun 19, 2019 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Feb 22, 2016 | Initial | $1,050,000 | No comparison | 2 | SEC filing |
| Apr 10, 2014 | Amendment | $4,386,221 | $2,017,221vs Mar 25, 2013 | 3 | SEC filing |
| Mar 25, 2013 | Initial | $2,369,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-370122
Equity to be acquired upon conversion of debt.
Source: Form D, filed Jul 1, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Judd Heberger | Director |
| Billie Jo Herberger | Director |
| Judd Herberger | Director |
| Paul Hergenrother | Director |
| Ted Tarasow | Director, Executive |
| Ron Way | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2001 S. First St. Suite 201
Champaign, IL, 61820
Champaign, IL, 61820